
zzso trials in cancer treatment present special problems in statistical zzso When the primary treatment zzso results in a relatively high cure rate and additional methods of treatment are being inserted in an effort to raise the figures to even higher levels, therapeutic benefit can be obscured unless all features of the study are carefully zzso zzso benefit may easily be masked by the sizable number of patients zzso to receive zzso treatment who have no residual tumor and therefore could not possibly benefit zzso For example, 50% of patients undergoing zzso zzso for colon cancer survive without evidence of disease beyond the five-year zzso zzso thus at least half the patients zzso to receive zzso treatment zzso zzso zzso will be zzso at the time of zzso and cannot benefit from zzso zzso New methods of assessment of treatment must be zzso otherwise, substantial therapeutic effectiveness may go zzso 

